March 9, 2024

Bismuth add-on improves the efficacy of 2-week tegoprazan-based triple therapy for first-line Helicobacter pylori eradication: a real-world evidence study

Key Points

Key points are not available for this paper at this time.

Abstract

Background This study aimed to investigate the efficacy of bismuth added to a 2-week triple therapy consisting of tegoprazan (TPZ), amoxicillin, and clarithromycin for first-line Helicobacter pylori eradication.

AIに質問

Bookmark

View Full Paper

Cite This Study

Jun‐Hyung Cho (Sat,) studied this question.

synapsesocial.com/papers/68e74cd0b6db6435876c55fa https://doi.org/https://doi.org/10.1080/14787210.2024.2329251

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Comparative Efficacy of 14-Day Tegoprazan-Based Triple vs. 10-Day Tegoprazan-Based Concomitant Therapy for Helicobacter pylori Eradication2022 · 18 citations
2Meta-Analysis of First-Line Triple Therapy for<i>Helicobacter pylori</i>Eradication in Korea: Is It Time to Change?2014 · 96 citations
3Bismuth encephalopathy- a rare complication of long-standing use of bismuth subsalicylate2019 · 51 citations
4Prevalence of Primary and Secondary Antimicrobial Resistance of <i><scp>H</scp>elicobacter pylori</i> in <scp>K</scp>orea from 2003 through 20122012 · 230 citations
5Bismuth: Environmental Pollution and Health Effects2011 · 59 citations

AIに質問

Bookmark

View Full Paper